phase 2_completion

Xijing Hospital — pertuzumab + trastuzumab (Phase II Trial Completion)

April 30, 2026pertuzumab + trastuzumabupdated 2mo ago

community read0 votes

Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Triple-Negative Breast Cancer (TNBC)